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Abstract 
 
This  study was carried out in three centers, Ribat University Hospital 
(Khartoum), Bahri  Diabetic Center (Khartoum North) and Imtyaz Diabetic Center 
(Omdurman).  
The main aims of this study were to investigate the presence of islet cell 
autoantibodies, differentiate between insulin dependence and insulin independence 
as well as to diagnose the prevalence of thyroid disorders among diabetes mellitus 
type two patients. 
Blood samples were taken from eighty eight (88) Sudanese type II diabetic 
patients (represented as 57.2% were female while 41.8% were males) and forty(40) 
apparently healthy individuals as control group as 50% for both sexes. The mean age 
was (50.3) and (48.7) years for the patients and the control groups respectively 
ranged between (40-65) year.  
Out of the total patients, 69.3% have family history of diabetes. The duration 
of the disease ranged between 1-10 years. All of  the patients received oral treatment 
(Insulin independence).  
Pancreatic autoantibodies were detected by using the Enzyme Linked 
Immuno Sorbant Assay (ELISA). To estimate the level of the thyroid hormones 
(T3 & T4) and the thyroid stimulating hormone (TSH) among diabetic patients, 
Radio Immune Assays (RIA/ IRMA) techniques were used to determine the 
relation between diabetes mellitus and thyroid gland disorders. The FBG was 
measured colourimetrically.   
A significant increase (p= 0.00) in FBG level was observed among the 
patients compared to the healthy subjects. Pancreatic autoantibodies were detected 
in 9 patients (10.2%), but no evidence of a relation between Fasting Blood Sugar 
 IV
(FBG) level and the pancreatic autoantibodies detected. Out of the 9 patients 
examined, 3 of them were shown to have thyroid disorders. 
 When the thyroid disorders were screened, 24 patients (27.3%) were found 
to have clinical, subclinical, hypo or hyper thyroidism from all the patients. 
Furthermore, TSH level(0.01) in patients with type II DM was significant low 
compared to the healthy group.  
There was a significant negative correlation between the FBG level and TSH 
hormone (0.038) while no correlation observed between FBG level and the T3 and 
T4. 
This study concluded that patients with blood glucose disturbances should  
examine pancreatic autoantibodies to differentiate the type of DM  in order to 
choose  the appropriate treatment. Further more, it is important to investigate the  
thyroid hormones and TSH annually to determine the clinical and subclinical  
dysfunctions  for the possible  early treatment and control of endocrine disorders. 
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  اﻟﺨﻼﺻﺔ
ﻣﺮآﺰ اﻟﺨﺮﻃﻮم ﺑﺤﺮي ﻟﻠﺴﻜﺮي , ﻣﺴﺘﺸﻔﻲ اﻟﺮﺑﺎط اﻟﺠﺎﻣﻌﻲ: ﻓﻲ ﺛﻼث ﻣﺮاآﺰ أﺟﺮﻳﺖ  هﺬﻩ اﻟﺪراﺳﺔ          
ﺟﺴﺎم ﻣﻀﺎدة أﻋﻦ وﺟﻮد  اﻟﻜﺸﻒاهﺪاف هﺬﻩ اﻟﺪراﺳﺔ اﻟﺮﺋﻴﺴﻴﺔ هﻲ . اﻻﻣﺘﻴﺎز ﺑﺎم درﻣﺎناﻟﻐﺪد اﻟﺼﻤﺎء و ﻣﺮآﺰ 
اﻟﺘﻤﻴﻴﺰ ﺑﻴﻦ ﻧﻮﻋﻲ اﻟﺴﻜﺮي اﻟﻤﻌﺘﻤﺪ ﻋﻠﻲ اﻻﻧﺴﻠﻴﻦ واﻟﻐﻴﺮ ﻣﻌﺘﻤﺪ ﻋﻠﻲ اﻻﻧﺴﻠﻴﻦ وﺗﺸﺨﻴﺺ , ﻟﻠﻐﺪة اﻟﻤﻌﺜﻜﻠﺔ
  .اﻧﺘﺸﺎر اﺿﻄﺮاﺑﺎت اﻟﻐﺪة اﻟﺪرﻗﻴﺔ وﺳﻂ ﻣﺮﺿﻲ اﻟﺴﻜﺮي اﻟﻨﻮع اﻟﺜﺎﻧﻲ
 ﻣﺼﺎﺑﻴﻦ ﺑﺎﻟﺴﻜﺮي اﻟﻨﻮع اﻟﺜﺎﻧﻲ)88(ﻋﻠﻲ ﻋﻴﻨﺎت دم ﻣﻦ ﺛﻤﺎﻧﻴﺔ وﺛﻤﺎﻧﻴﻦ هﺬﻩ اﻟﺪراﺳﺔ ﺗﻢ اﻟﺤﺼﻮل ﻓﻲ  
آﻤﺠﻤﻮﻋﺔ  ﻟﻜﻞ ﻧﻮع %05ﺑﻨﺴﺒﺔ  ﺻﺤﺎءﻓﺮد أارﺑﻌﻴﻦ و , ﻟﻠﺮﺟﺎل%  2.75ﻟﻠﻨﺴﺎء و %  2.14ﻣﻤﺜﻠﻴﻦ ب 
 .ﺳﻨﺔ 56- 04ﺑﻴﻦ  ﻣﺘﺮاوﺣًﺎﺳﻨﺔ ﻟﻼﺻﺤﺎء واﻟﻤﺮﺿﻲ ﻋﻠﻲ اﻟﺘﻮاﻟﻲ  3.05و  7.84ﻣﺘﻮﺳﻂ اﻻﻋﻤﺎر ﺑﻴﻦ . ﺗﺤﻜﻢ
ﺗﺘﺮاوح ﻣﺪة . ﻟﻠﺴﻜﺮي ﻣﻦ اﻟﻤﺮﺿﻲ ﻟﺪﻳﻬﻢ ﺗﺎرﻳﺦ ﻣﺮﺿﻲ %3.96 هﻨﺎك, اﻟﻜﻠﻲ ﻣﻦ ﻣﺠﻤﻮع اﻟﻤﺮﺿﻲ 
  (.ﻏﻴﺮ ﻣﻌﺘﻤﺪﻳﻦ ﻋﻠﻲ اﻻﻧﺴﻮﻟﻴﻦ) ﻳﺘﻠﻘﻮن ﻋﻼج ﺑﺎﻟﻔﻢ اﻟﻤﺮﺿﻲ ﺟﻤﻴﻊ. ﺳﻨﺔ( 01- 1)ﺑﻴﻦ ﺻﺎﺑﺘﻬﻢ ﺑﺎﻟﻤﺮضإ
ﺎﺳﺘﺨﺪام ﻃﺮﻳﻘﺔ اﻟﻤﻘﺎﻳﺴﺔ ﺑ ﺗﻢ ﻗﻴﺎﺳﻬﺎ ﻤﻀﺎدة ﻟﻠﻐﺪة اﻟﻤﻌﺜﻜﻠﺔ  ﻓﻲ ﻣﺮض اﻟﺴﻜﺮي اﻟﻨﻮع اﻟﺜﺎﻧﻲاﻟﺟﺴﺎم اﻻ
واﻟﻬﺮﻣﻮن اﻟﻤﻨﺸﻂ ﻟﻠﻐﺪة ( 4ﺗﻲ )و ( 3ﺗﻲ)ﻘﻴﺎس ﻣﺴﺘﻮي هﺮﻣﻮﻧﺎت اﻟﻐﺪة اﻟﺪرﻗﻴﺔﻟ (.اﻟﻴﺴﺎ) اﻻﻧﺰﻳﻤﻴﺔاﻟﻤﻨﺎﻋﻴﺔ 
ﻟﻤﻌﺮﻓﺔ اﻟﻌﻼﻗﺔ ﺑﻴﻦ اﺿﻄﺮاﺑﺎت  (ار اي اﻳﻪ) اﻟﻤﻘﺎﻳﺴﺔ اﻟﻤﻨﺎﻋﻴﺔ اﻻﺷﻌﺎﻋﻴﺔﺑﺎﺳﺘﺨﺪام ( ﺗﻲ أس اﺗﺶ)اﻟﺪرﻗﻴﺔ 
ﺑﺎﺳﺘﺨﺪام ﺟﻬﺎز اﻟﻄﻴﻒ  ﻟﺠﻠﻜﻮزا ﺗﻢ ﻗﻴﺎس .واﺿﻄﺮاﺑﺎت اﻟﻐﺪة اﻟﺪرﻗﻴﺔ (اﻟﺴﻜﺮي اﻟﻨﻮع اﻟﺜﺎﻧﻲ)اﻟﻐﺪة اﻟﻤﻌﺜﻜﻠﺔ
  .اﻟﻠﻮﻧﻲ
ﻓﻲ ﻣﺴﺘﻮي اﻟﺠﻠﻜﻮز ﻋﻨﺪ هﺆﻻء اﻟﻤﺮﺿﻲ ﻣﻘﺎرﻧﺔ ( 000.0)ﻟﻮﺣﻆ ارﺗﻔﺎع ذو ﻗﻴﻤﺔ ﻣﻌﻨﻮﻳﺔ ﻗﻮﻳﺔ          
ﺑﻴﻨﻤﺎ ﻟﻢ ﻳﺜﺒﺖ وﺟﻮد اي ﻋﻼﻗﺔ %(  2.01)ﻣﺮﺿﻲ 9ﻤﻀﺎدة ﻟﻠﻐﺪة اﻟﻤﻌﺜﻜﻠﺔ ﻓﻲ اﻟﺟﺴﺎم ﺷﺨﺼﺖ اﻻ .ﺑﺎﻻﺻﺤﺎء
ﺛﻼﺛﺔ ﻣﻦ هﺆﻻء اﻟﻤﺮﺿﻲ ﺗﻢ ﺗﺸﺨﻴﺺ ﺧﻠﻞ ﻓﻲ  .ﺟﺴﺎم اﻟﻤﻀﺎدةاﻻ هﺬﻩ ﺑﻴﻦ ﻣﺴﺘﻮي اﻟﺠﻠﻜﻮز ﻓﻲ اﻟﺪم ووﺟﻮد
 .وﻇﺎﺋﻒ اﻟﻐﺪة اﻟﺪرﻗﻴﺔ ﻟﺪﻳﻬﻢ
ﺗﻢ ﺗﺸﺨﻴﺺ ارﺑﻌﺔ وﻋﺸﺮﻳﻦ ﻓﺮد ﻟﺪﻳﻬﻢ ﺧﻠﻞ ﻓﻲ ﻣﺴﺘﻮي هﺮﻣﻮﻧﺎت اﻟﻐﺪة اﻟﺪرﻗﻴﺔ او ﺧﻠﻞ ﺗﺤﺖ ﺳﺮﻳﺮي           
ﻣﻠﺤﻮظ ذا اﻇﻬﺮت هﺬﻩ اﻟﺪراﺳﺔ اﻧﺨﻔﺎض و, %(3.72)ﻣﻦ ﺟﻤﻠﺔ اﻟﺜﻤﺎﻧﻴﺔ واﻟﺜﻤﺎﻧﻴﻦ اﻟﻤﺼﺎﺑﻴﻦ ﺑﺪاء اﻟﺴﻜﺮي 
آﻤﺎ ان , ﻓﻲ اﻟﻬﺮﻣﻮن اﻟﻤﺤﻔﺰ ﻟﻠﻐﺪة اﻟﺪرﻗﻴﺔ ﻋﻨﺪ ﻣﺮﺿﻲ اﻟﺴﻜﺮي اﻟﻨﻮع اﻟﺜﺎﻧﻲ ﻣﻘﺎرﻧﺔ ﺑﺎﻻﺻﺤﺎء( 10.0)ﻣﻌﻨﻲ 
ﺑﻴﻨﻤﺎ ﻟﻢ ﻳﺜﺒﺖ وﺟﻮد اﺧﺘﻼف   (30.0) اﻟﺪم ﺑﻴﻦ ﻣﺴﺘﻮي اﻟﺠﻠﻜﻮز ﻓﻲ ﺑﻴﻨﻪ و هﻨﺎك ﻋﻼﻗﺔ ﻋﻜﺴﻴﺔ ﻗﻮﻳﺔ ذات ﻣﻌﻨﻲ
ﻋﻨﺪ ﻣﺠﻤﻮﻋﺘﻲ اﻟﻤﺮﺿﻲ واﻟﺘﺤﻜﻢ وﻻﺗﻮﺟﺪ ﻋﻼﻗﺔ ذا ﻣﻌﻨﻲ ﺑﻴﻦ ﻧﺴﺒﺔ اﻟﺜﻴﺮوآﺴﻴﻦ واﻟﺜﻴﺮوآﺴﻴﻦ ﺛﻼﺛﻲ اﻟﻴﻮد 
  .ﻣﻌﻨﻮﻳﺔ آﺬﻟﻚ ﺑﻴﻦ هﺬﻳﻦ اﻟﻬﺮﻣﻮﻧﻴﻦ وﻣﺴﺘﻮي اﻟﺠﻠﻜﻮز ﻓﻲ اﻟﺪم
ﻓﺤﺺ اﻻﺟﺴﺎم اﻟﻤﻀﺎدة  ﻻن اﻟﻤﺮﺿﻲ اﻟﻤﺼﺎﺑﻴﻦ ﺑﺎﺿﻄﺮاﺑﺎت ﺳﻜﺮ اﻟﺪم ﻋﻠﻴﻬﻢﺗﻮﺻﻠﺖ هﺬﻩ اﻟﺪراﺳﺔ       
ﻓﺔ اﻟﻲ اﻧﻪ ﻣﻦ اﻟﻀﺮوري ﺗﺤﻠﻴﻞ اﺿﺎآﻤﺎ  .اﻟﻤﻨﺎﺳﺐﺘﺤﺪﻳﺪ اﻟﻌﻼج ﻟاﻟﺬاﺗﻴﺔ ﻟﻠﻐﺪة اﻟﻤﻌﺜﻜﻠﺔ ﻟﺘﺤﺪﻳﺪ ﻧﻮع اﻟﺴﻜﺮي 
IV 
اﻟﺴﺮﻳﺮي وﺗﺤﺖ اﻟﺴﺮﻳﺮي  ﻞﻟﺘﺤﺪﻳﺪ اﻟﺨﻠ ﺳﻨﻮﻳًﺎ اﻟﻬﺮﻣﻮن اﻟﻤﺤﻔﺰ ﻟﻠﻐﺪة اﻟﺪرﻗﻴﺔواﻟﻐﺪة اﻟﺪرﻗﻴﺔ هﺮﻣﻮﻧﺎت 
 .اﻟﺘﺤﻜﻢ ﻓﻲ اﺿﻄﺮاﺑﺎت اﻟﻐﺪد اﻟﺼﻤﺎء واﻟﻌﻼج اﻟﻤﺒﻜﺮ  ﻻﻣﻜﺎﻧﻴﺔ
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CHAPTER ONE 
INTRODUCTION 
 
  Diabetes mellitus comprises a heterogeneous group of disorders 
characterized by high blood glucose levels. Four major types of diabetes 
have been defined: insulin-dependent diabetes mellitus (IDDM), non-
insulin-dependent diabetes mellitus (NIDDM), gestational diabetes mellitus 
(GDM), and diabetes secondary to other conditions. Diabetes mellitus 
affects more than 150 million people worldwide and this number is expected 
to double within the next two decades (Moore and Florez, 2008). 
        There is an increasing prevalence of non-communicable diseases in 
developing countries due to the aging of the population and lifestyle changes 
accompanied by urbanization and westernization. A rapid increase of such 
diseases has been observed in these regions despite improved standards in 
living conditions which differ substantially from those in the western world. 
An increased incidence of diabetes of  both insulin requiring and non-insulin 
requiring diabetes has already been observed in industrialized countries and 
is now being observed in Africa and poor countries (Hawa et al., 2005). 
      Recently,  Latent Auto immune Disease in adults (LADA), was coined 
by Tuomi et al (1993) to describe patients with a slowly progressive form of 
autoimmune or type 1 diabetes which could be treated initially without 
insulin injections. This clinical observation was intended to distinguish 
LADA from classic type 1 diabetes, where insulin is required after 
diagnosis, and from type 2 diabetes, where insulin is not required at all or at 
least until some years after diagnosis (Toumi et al., 1993). 
       Latent autoimmune diabetes in adults (LADA) and type 1 diabetes 
mellitus result from islet beta cell autoimmune destruction and are  
2 
 
characterized by the presence of circulating islet autoantibodies. However, 
the later age of    onset and the relatively less acute clinical onset of LADA 
can result in clinical diagnosis of type 2 diabetes (Arneson and Brickell, 
2007). 
The physiological and biochemical interrelationship between insulin 
and the influence of both insulin and iodothyronines on the metabolism of 
carbohydrates, proteins and lipids are recorded (Udiong et al., 2007). Such 
records indicate that iodothyronines are insulin antagonists with high levels 
being diabetogenic, while absence of the hormone inhibits the development 
of diabetes. Diabetes mellitus and hyperthyroidism are metabolic disorders 
that affect the levels of carbohydrates, proteins and lipids (Udiong et al., 
2007). 
 Diabetes mellitus and thyroid diseases are the two common 
endocrinopathies seen in the adult population. With insulin and thyroid 
hormones being intimately involved in cellular metabolism and thus excess 
or deficit of either of these hormones could result in the functional 
derangement of the other (Sathish and Mohan, 2003). 
 Currently there is little   data on the relation between diabetes 
mellitus that this problem has not get sufficient  attention yet especially in 
Sudan where the diabetes gets continuous increasing impact and many 
studies suggest a great benefit for the early detection of thyroid disturbances 
on DM which is considered as one of the risk factors. 
 Moreover, the early diagnosis of both thyroid dysfunction and latent 
autoimmune disease in DM patients is highly important to control the 
disease and survive with better conditions, less complications and the 
effective therapy approaches. 
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Objectives: 
The objectives of the present study were as follows:  
     (1) To detect the presence of islet cell autoantibodies (GAD65 & IA2) in 
clinically diagnosed type II patients with view to be classified as having 
latent autoimmune diabetes in adults (LADA). 
     (2) To differentiate between insulin dependent and independent diabetic 
patients for proper treatment and management. 
    (3) To determine the prevalence of undiagnosed thyroid diseases among 
diabetes mellitus type II and reveal the association between diabetes and 
thyroid dysfunctions. 
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Chapter Two 
Literature Review 
 
2. 1. Diabetes mellitus:  
         Diabetes Mellitus (DM) comprises a heterogeneous group of disorders 
characterized by high blood glucose level and is caused by an absolute (type 
I) or relative (type II) lack of insulin (Akbar et al., 2006). Approximately, 
6% of the world’s population suffers from diabetes mellitus and this is set to 
rise to 300 million sufferers by 2025(Adeghate et al., 2006). 
       Diabetes is characterized by polyurea, polydipsia, hyperglycaemia, 
glycosuria, ketosis, acidosis and coma. There are wide spread biochemical 
abnormalities but the fundamental defects to which most of the 
abnormalities can be traced are reduced entry of glucose into various 
peripheral tissues and increase liberation from the liver. There is therefore an 
extracellular glucose excess and in many cells, and intracellular glucose 
deficiency, there is also decrease in the entry of amino acids and an increase 
in lipolysis (Ganong, 2003).  
      Because of trends in obesity and sedentary lifestyles, diabetes rates in 
both developed and developing countries are increasing at an alarming rate. 
Current medications are not adequately effective in maintaining long-term 
glycemic control in most patients, even when used in combination, leaving 
diabetics susceptible to developing life threatening and debilitating 
complications such as cardiovascular disease, blindness, kidney 
complications, and amputations. Consequently, there is a critical need for 
more potent pharmacotherapies with novel mechanisms of action (Mohler et 
al., 2008). 
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 2.2. Classification of Diabetes mellitus:  
       Four major types of diabetes have been defined: insulin- dependent 
diabetes mellitus (IDDM), non-insulin-dependent diabetes mellitus 
(NIDDM), gestational diabetes mellitus (GDM) and diabetes secondary to 
other conditions.  The major diabetes types are believed to include different 
stages of disease, ranging from non–insulin-requiring to insulin-requiring for 
control or survival. According to this classification adopted by the World 
Health Organization (WHO), it is quite possible that both processes would 
operate in a single patient and contribute to the phenotype of the patient. 
Also, factors other than autoimmunity can lead to a defective insulin 
response to glucose. Both major diabetes types are considered multifactorial 
diseases with several predisposing genetic and environmental factors, some 
of which could be common to both types. In populations with a high 
prevalence of type 1 diabetes, like in Finland, a large proportion of patients 
with type II diabetes should have inherited susceptibility genes for both 
types of diabetes. Also, the lifestyle changes leading to the type II diabetes 
epidemic around the world (Zimmet et al, 2001). 
2.2.1 Insulin –dependent diabetes mellitus (IDDM) : 
       The disease is characterized by absolute deficiency of insulin caused by 
massive autoimmune attack in the β cells of the pancreas. This destruction 
requires a stimulus from the environment (such as a viral infection) and 
genetic determinant that allows the β cells to be recognized as non self. The 
islet of  Langerhans become infiltrated with activated T-lymphocytes leading 
to condition called insulitis  over  a period of years , This autoimmune attack 
leads to gradual depletion  of  β cell population and eventually loss of insulin 
production  (Pamela and Richard, 1994; Peter, 1982). 
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 2.2.2. Non-Insulin –dependent diabetes mellitus (NIDDM):  
       Type 2 diabetes is the most common form of the disease. It develops 
gradually without obvious symptoms. The disease is often detected by 
routine screening tests. Patients secrete insulin and their serum concentration   
may be diminished, normal or even increased. The cause is unknown but the 
best one is obesity (Peter, 1982; Frazade et al., 2006).  
         Type 1 disease usually occurs as acute illness, while type II diabetes 
progresses slowly over time. Type 1 glucose blood levels are usually more 
severe than type II. Type 1 diabetics are more likely to develop ketoacidosis 
than are type II diabetics. Due to the etiology of disease, type 1 diabetics are 
insulin dependents, while most type II diabetics are not. Type 1 diabetics are 
younger (<18 years old when diagnosed) and thinner; type II diabetics are 
usually older (>40 years old when diagnosed) and more likely to be obese. 
However, these characteristics of presentation are not uniform to all type 1 
and type II diabetics. Type 1 diabetes may be diagnosed after the age of 18 
years. Type II diabetes may develop in obese children. Type II diabetics may 
need insulin if glycemia cannot be controlled by other measures (Arneson 
and Brickell, 2007). 
        Gestational diabetes is similar in etiology to type II diabetes; however, 
it is defined as diabetes that is diagnosed in pregnancy. Pregnancy is 
associated with increased tissue cell resistance to insulin. Most pregnant 
women will compensate with increased secretion of insulin; those 
individuals who are unable to compensate may develop gestational diabetes, 
while secondary diabetes may be the secondary result of non–insulin-related 
events. Blood glucose levels are increased in endocrine disorders, such as 
Cushing’s syndrome; in exocrine disorders, such as cystic fibrosis, genetic 
defects that affect pancreatic beta cells or the action of insulin and as a 
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response to specific drugs, such as protease inhibitors and glucocorticoids 
(Arneson and Brickell, 2007).  
The prevalence of Type II diabetes (T2D) varies widely across ethnic 
groups, with incidence rates as low as 1% in some rural Asian populations 
while Pima Indians and Polynesians have among the highest diabetic 
incidence rates in the world, reaching the 30%–50% range. The offspring of 
a diabetic parent has a 40% chance of developing diabetes in contrast to a 
population risk of 7%, and if both parents are affected, the risk rises to 70% 
(Moore & Florez, 2008). However, the true prevalence is difficult to 
ascertain, because most patients are diagnosed with type 1 diabetes at an age 
when their parents, or grandparents, might still be too young to have 
developed type I diabetes. Also, reliable age-adjusted prevalence data for 
type II diabetes in the general population is rarely available (Toumi, 2005). 
2.3 Insulin Resistance: 
         Early stages of diabetes (stages 1 and 2 which are preclinical and 
clinical pre-diabetes (or metabolic syndrome), respectively can be 
characterized as progressively worsening insulin sensitivity in insulin target 
organs (i.e insulin resistance, IR) (Vialettes and Valero, 2003; Weir and 
Bonner-weir, 2004). 
There are three major acquired factors contributing to insulin 
resistance: visceral obesity, glucotoxicity and lipotoxicity. IR is a broad term 
which indicates that the normal effects of insulin on a tissue are reduced to 
some degree (Mohler et al., 2008). 
        The risk of diabetes increases linearly in relation to body mass index 
(BMI); diabetes prevalence was 2%, 8%, and 13% in those with a BMI 25–
29.9 kg/m2 (overweight), 30–34.9 kg/m2 (class I obesity), and 35 kg/m2 
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(class II/III obesity), respectively. In the Nurses Health Study the risk of 
diabetes was found to increase above a BMI of 22 kg/m2 (Segal, 2004). 
2.4. Complications: 
       In both types of diabetes, the management of the disease is costly and 
requires the use of insulin and oral hypoglycemic drugs. Health care 
infrastructure in the developing countries is inadequate in many areas, and 
furthermore, medication is either unavailable or often unaffordable. 
Therefore, the form of anti-diabetic therapy depends, to a degree, on which 
drugs are available. As a result, African populations with diabetes have high 
rates of acute and long-term complications including increased mortality.  At 
the dawn of the third millennium, life expectancy in a patient with type 1 
diabetes in some regions of Africa can be as short as 12 months. In Africa, 
different forms of diabetes are diagnosed including type 1 diabetes, type 2 
diabetes, malnutrition related diabetes mellitus and tropical diabetes, an 
atypical form of the disease (Hawa et al., 2006). 
        The most commonly observed signs of diabetes risk include advanced 
age, abdominal obesity, and sedentary life style which, independent of 
diabetes, also increase the risk of cardiovascular diseases. Metabolic 
syndrome is a pre-diabetic state which is now recognized by physicians that 
consists of glucose intolerance and a variety of cardiovascular risk factors to 
include abdominal obesity, atherogenic dyslipidemia (triglycerides (TG) 
>150mg/dl; high density lipoprotein (HDL) <40 mg/dl in men; <50 mg/dl in 
women), hypertension (>130/85 mmHg) or anti-hypertensive 
pharmacotherapy, insulin resistance and inflammatory or prothrombotic 
states. Diabetes also significantly contributes to populations with blindness, 
kidney failure (diabetic nephropathy accounted for 44% of renal failure in 
2002), nerve and foot amputations (leading cause of amputations owing to 
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neuropathy coupled to impaired immunity). This damage, most commonly, 
is a result of glycation of the tissues such as the microvasculature (eye, 
kidney, and nerves) caused by the high glucose levels (Mohler et al., 2008). 
2.5. Diabetes mellitus in Sudan: 
       Diabetes mellitus in Sudan constitutes a growing health problem with a 
major impact. Non insulin dependent account for 75% of all diabetic patients 
attending diabetic clinics in Khartoum (Elmahdi et al., 1989). In a more 
recent study 95% of all patients were classified as having NIDDM; however 
75% were treated with insulin (Bani et al., 1994). 
       In both studies, the classification of insulin dependence was based on 
early onset of diabetes (< 15 years) and previous history of diabetic 
ketoacidosis. Obesity was a feature characterizing 39-40% of all diabetic 
patients, and strong association with family history of the disease was 
reported (Elmahdi et al., 1989; Bani et al., 1994). 
      IDDM in Sudan among children 7-14 years of age, is not rare in Sudan, 
and showed steady rise in the incidence rate over 4 years period (Elamin et 
al., 1989). Among children and adolescents almost all those with diabetes 
were poorly controlled and received a minimum diabetic care. Both acute 
and long term complications were more common among these children 
(Elamin et al., 1989). The poor metabolic control of Sudanese diabetic 
patients was attributed to the poor compliance and poor knowledge of 
diabetes and to problem associated with injections and drug availability 
(Elmahdi et al., 1989). 
2.6. Diagnosis of diabetes: 
       The diagnosis of diabetes is made upon repeated failure in fasting 
plasma glucose test (FPG; >126 mg/dl) or oral glucose tolerance test 
(OGTT; >200 mg/dl 2 hr after glucose challenge) on two separate days. The 
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failure of the body to clear dietary glucose is an indication that glucose 
metabolism is aberrant and suggests either a deficient insulin secretion from 
the pancreas or an inability of the body to adequately respond to the insulin 
that is present. The focus of diabetic monitoring is glycemic control via self-
monitored blood glucose (SMBG) to determine FBG and post-prandial 
glucose clearance, and laboratory testing for levels of glycation of 
hemoglobin A (Arneson and Brickell, 2007). 
        HbA1c, a glycated hemoglobin, is an indicator of long-term glycemic 
control. The level of glycated hemoglobin in a blood sample provides a 
glycemic history of hemoglobin glycation and the average glucose levels in 
the blood over the life span of the erythrocyte, 120 days (Little et al., 2001). 
        Since type 1 diabetes is characterized by low levels of insulin and type 
II diabetes usually characterized by normal or high levels of insulin, it might 
appear that the results of blood insulin tests would be the means for 
distinguishing between type 1 and type 2 diabetes. However, the difficulty in 
measuring this hormone accurately diminishes its usefulness for diagnosis 
(Arneson and Brickell, 2007). 
2.7. Islet cell Autoantibodies: 
       Autoantibodies are created by the immune system when it fails to 
distinguish between “self” and “nonself.” It is normally trained to recognize 
and ignore the body’s own cells and to not overreact to non-threatening 
substances in the environment. At the same time, the immune system must 
be able to create antibodies that target and fight specific foreign substances 
that do pose a threat. The bad news is, when this highly regulated and 
efficient system is turned onto self-antigens, target tissue damage ensues. 
Autoantibodies that bind to specific proteins found in the pancreatic islet 
cells were first described 30 years ago (Pihoker, 2005).  
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2.8. Diabetes and Autoantibodies: 
          The appearance of autoantibodies to one or several of the autoantigens 
GAD65, IA-2, or insulin—signals an autoimmune pathogenesis of β cell 
killing. A-cell attack may be best reflected by the emergence of 
autoantibodies dependent on the genotypes risk factors, isotypes, and 
subtype of the autoantibodies as well as their epitopes specificity. It is 
speculated that progression to-cell loss and clinical onset of type 1 diabetes 
is reflected in a developing pattern of epitope specific autoantibodies. 
Although the appearance of autoantibodies does not follow a distinct pattern, 
the presence of multiple autoantibodies has the highest positive predictive 
value for type 1 diabetes. In the absence of reliable T-cell tests, dissection of 
autoantibody responses in subjects of genetic risk should prove useful in 
identifying triggers of islet autoimmunity by examining seroconversion and 
maturation of the autoantibody response that may mark time to onset of type 
1 diabetes. The complexity of the disease process is exemplified by multiple 
clinical phenotypes, including autoimmune diabetes masquerading as type 2 
diabetes in youth and adults. Autoantibodies may also provide prognostic 
information in clinically heterogeneous patient populations when examined 
longitudinally (Pihoker, 2005). 
        Diabetes autoantibodies, reflecting activation of the immune system 
 and β-cell response, are used at diagnosis to establish an autoimmune 
disease process. The presence of autoantibodies to one of a number of islet 
cell autoantigens has been used to identify the preclinical autoimmune 
process in at-risk patients, or to confirm that a patient’s diabetes is 
autoimmune in etiology. Because autoantibodies have become a practical 
measure of autoimmunity, it is important to recognize factors unrelated to 
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diabetes type that affect the presence of autoantibodies. Children are more 
likely than adults to be positive to multiple autoantibodies, and they are 
much more likely to have Insulin Auto Antibodies (IAAs) present at 
diagnosis. In young children under the age of 10, IAAs are present 
approximately 50% - 60% of the time, but the frequency of positive IAAs in 
adults is only 10% (Pihoker , 2006). GAD 65Ab are present approximately 
70% - 80% of the time, although they are slightly less common under the 
age of 10 years, especially in boys (Winter, et al 2002). 
2.9. Glutamic Acid Decarboxylase (GAD65):  
The 65-kDa isoform of glutamic acid decarboxylase (GAD65) is a 
major autoantigen in Type 1 diabetes. Antibody epitopes on GAD65 initially 
were localized by expression of truncated proteins from deletion mutants of 
cDNARs or by creation of swap mutants in which sequences of GAD65 
were replaced by homologous sequences of the nonautoantigenic isoform, 
GAD67. Two main epitope regions of GAD65 for diabetes sera, and for 
various monoclonal islet cell antibodies (MICAs), were located, one in the 
midregion, in the vicinity of the attachment site for the pyridoxal phosphate 
(PLP) cofactor, and one in the C terminal region; but again, the lengths of 
these epitope regions indicated a conformational structure (Mackay &  
Rowley, 2004). 
        GAD65Ab are more common in patients with other autoimmune 
disorders, such as thyroiditis. It is also of interest to examine autoantibodies 
and other autoimmune markers in children and adolescents with clinical 
features of type 2 diabetes. The frequency of positive autoantibodies in type 
2 diabetes in children has been higher than expected (Pihoker 
13 
 
, 2006). Hathout et al (2001) reported that approximately one third of 48 
children with a clinical diagnosis of type 2 diabetes had positive GAD65Ab 
and IAA (30.3% and 34.8%, respectively). 
  In another study, autoantibodies and T-cell reactivity were examined 
in a racially and ethnically diverse groups of children with a clinical 
presentation of type 1, type 2, or mixed features (obesity, acanthosis 
nigricans, and ketosis without acidosis). A total of 71% had at least one 
positive autoantibody (GAD 65Ab, IA2, IAA, or ICA) and 34% had T-cell 
reactivity to islet proteins, as is observed in type 1 diabetes (Brooks-Worrell 
et al, 2004). In the United Kingdom Prospective Diabetes study, 4% - 21% 
of subjects were found to have positive GAD 65Ab (Pihoker, 2006). 
Autoimmune diabetes (hyperglyceamia associated with serological 
markers of pancreatic β cell autoimmunity) occurring in adults has a 
relatively slow onset compared with childhood onset. Type 1 diabetes is 
usually diagnosed and treated as Type 2 diabetes; most of these adult-onset 
(typically over the age of 30 years) patients retain adequate residual B-cell 
function to prevent ketoacidosis and avoid the need for insulin replacement 
therapy for a number of years. This subgroup of patients is usually only 
distinguished from those with classical Type 2 diabetes by testing for 
autoantibodies against-cell proteins and is most commonly called latent 
autoimmune diabetes in adults (LADA). Other nomenclature includes slowly 
progressive insulin-dependent diabetes, latent Type 1 diabetes, Type 1 
diabetes masquerading as Type II diabetes and Type 1.5 diabetes. Although 
the presence of autoimmune diabetes developing in adults has been 
recognized for more than 30 years, LADA remains a clinical controversy. 
Immunological, genetic and physiological studies on large and small cohorts 
14 
 
in different parts of the world have provided often conflicting evidence to 
support or disprove LADA as a separate disease entity (Desai et al, 2007).    
A recent proposal for diagnostic criteria for LADA as age > 30 years at 
clinical presentation and not requiring insulin for > 6 months post-diagnosis 
might aid definition of this disease (Palmer et al, 2005). LADA patients 
represent a variable proportion (2–22%) of diagnosed Type 2 diabetic 
subjects, depending on the ascertainment criteria and population (Desai et al, 
2007).  
          Insulin resistance is a primary component in the pathophysiology of 
type 2 diabetes. In latent LADA, insulin resistance has been reported to be 
significantly lower than in autoantibody-negative type 2 diabetes (T2DM), 
but whether this might be related to differences in body mass index (BMI) 
has not been excluded. Furthermore, previous studies have used limiting 
inclusive criteria for LADA, requiring only the presence of GADA or IA-
2A. To apply more inclusive criteria for LADA, consistent with recent 
recommendations, LADA was defined by clinical manifestations 
characteristic of T2DM, but with the presence of any combination of 
GADA, IA-2A, ICA, or IAA. 43 LADA patients, 70 T2DM patients, and 
150 non-diabetic controls were recruited. Insulin resistance was assessed by 
both the homeostasis model assessment and the quantitative insulin 
sensitivity check index, and BMI was calculated that insulin resistance in 
LADA is equivalent to that of T2DM. When insulin resistance is assessed as 
a function of BMI, both diabetic populations demonstrated an insulin 
resistance equally greater than normal controls. The interaction between 
insulin resistance and BMI in the two diabetic groups was   significantly 
different from that demonstrated in non-diabetic controls. In summary, 
LADA demonstrates insulin resistance of similar magnitude to T2DM, but 
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with the concurrent component of an immune attack against the pancreatic 
beta-cells. LADA patients may be at significant risk for metabolic 
consequences of insulin resistance other than glucose metabolism, such as 
those described in the metabolic syndrome (Chiu et al, 2007). 
 In Africa, there are little data on the prevalence and immunological 
features of patients with autoimmune endocrine diseases. A study from 
Congo, surprisingly, showed that high number (11%) of established adult-
onset diabetic patients have GAD autoantibodies suggesting that even in 
them there is an autoimmune form of diabetes (Guglielmi et al, 2004).  
Another study achieved in Cameron by Hawa et al, (2005), showed that of 
18 patients with thyrotoxicosis, 4 (22.2%) had GAD Abs, 5 (27.8%) showed 
IA2 Abs, while 8 patients (44.4%) were TPO Abs positive. Patients with 
thyrotoxicosis had a similar frequency of diabetes-associated autoantibodies. 
That means despite a different genetic and environmental background to 
European populations, islet cell autoimmunity is common in autoimmune 
endocrine patients in central Africa (Hawa et al, 2005). 
2.10. Thyroid gland: 
         The thyroid gland is divided into lobules, each with 20-40 follicles and 
a distinct vascular supply. Each lobule has 20–40 follicles, and follicles are 
the basic functioning units of the thyroid gland. The lumen of each follicle is 
filled with viscous colloid identified as the glycoprotein thyroglobulin which 
contains the molecular structure and is the precursor of all thyroid hormones. 
Thyroperoxidase (TPO) is a membrane-bound enzyme found on the surface 
of the follicular cells which is to catalyze iodide into an active intermediate. 
After thyroid hormones are synthesized and secreted into the serum, they are 
bound to serum carrier proteins, the Thyroid Binding Protein (TBG), 
thyroxine-binding prealbumin, and albumin. Normal thyroid hormone 
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synthesis requires an adequate iodine intake of 150g in adolescents and 
adults, 200g  in pregnancy, and 90–120g in children. Thyroid hormones 
enter cells by diffusion and carrier-mediated transport and bind to nuclear 
TSH receptors. TSH receptors are found on the surface of the follicular cells 
within the thyroid as well as on adipocytes, lymphocytes, fibroblasts, and 
gonads. This is important because TSH stimulates adipocyte lipolysis. T4 
and to a small degree T3, circulating in the serum inhibits secretion of TSH 
and  the Thyrotropein Releasing Hormone (TRH), thereby completing the 
feedback cycle (Johnson, 2006). 
2.11. The Role of the Thyroid hormones: 
         Thyroid physiology is based on a regulatory feedback system typically 
found in endocrine systems. The hypothalamus secretes thyrotropin 
releasing hormone (TRH), which stimulates the anterior pituitary gland to 
secrete thyrotropin or TSH. TSH increases iodide uptake and oxidation that 
leads to organification and coupling, which are necessary steps to produce 
the thyroid hormones T4 and triiodothyronine (T3). TSH also stimulates 
growth and vasculature of the thyroid that could potentially lead to a goiter if 
excessive. Of the thyroid hormone secreted, 90% is T4 and 9% is T3. T3 
derives from deiodination of T4; therefore, 80% of circulating T3 is from 
T4. During serious debilitating illness or starvation, T3 production is 
reduced, possibly as a control mechanism to reduce the metabolic rate, 
which may be useful during recovery (Porterfield, 1997). 
        Iodine deficiency leads to decreased thyroid hormone synthesis, which 
in turn leads to increased TSH secretion and increased gland growth or 
goiter. Gland size, however, does not indicate thyroid function. Therefore, a 
goiter can be present in hypothyroidism, hyperthyroidism, or euthyroidism. 
(Johnson, 2006). 
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        Thyroid hormone exerts influences on numerous body systems, 
including growth and development, muscular function, sympathetic nervous 
system function, cardiovascular system, and carbohydrate metabolism. It is 
necessary for maturation and differentiation during development. Children 
with hypothyroidism show bone maturation delays as well as delayed or 
absent puberty and stunted growth because inadequate thyroid hormone 
secretion lowers growth hormone. They also plays an important role in lung 
maturation and normal fetal and neonatal brain development by regulating 
neuronal proliferation and differentiation, myelinogenesis, neuronal 
outgrowth, and synapse formation. The critical time for brain development 
starts in utero and continues to age. Deficiency can lead to structural and 
physiological impairment resulting in brain damage or severe neurological 
impairment (Johnson, 2006). 
      Thyroid function was classified as normal, if both TSH and free T4 were 
within their reference ranges; hypothyroid if TSH was elevated and 
hyperthyroid if TSH was suppressed. Hypothyroidism and hyperthyroidism 
were further classified as overt if free T4 was outside the reference range, 
and subclinical if free T4 was normal (Bedone et al., 2008). 
       Thyroid diseases are generally grouped into those that are due to 
reduced activity of the gland (hypothyroidism) and those due to overactivity 
(hyperthyroidism). The former are more common in older people. The forms 
of thyroid disorders include nontoxic goiter, Graves’disease, Hashimoto’s 
thyroiditis and thyroid neoplasm (Rallison et al., 1991).  
      The two main disorders that comprise autoimmune thyroid disease are 
Hashimoto thyroiditis and Graves disease. The former is the most common 
cause of hypothyroidism, whereas the latter is a major cause of 
hyperthyroidism. (Lamfon, 2008). 
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2.12. Thyroid Disease Prevalence: 
        The prevalence of thyroid disease in the general population is estimated 
to be 6.6%, with hypothyroidism the most common malady. 9.5% were 
found to have an elevated TSH level. Also, 6% of study participants were 
diagnosed with thyroid disease before the screening. However, 40% of those 
already diagnosed had elevated TSH levels, indicating inadequate treatment. 
In the undiagnosed population with TSH elevations, 9.9% were found to 
have an unrecognized thyroid abnormality. Several studies have documented 
a higher prevalence of thyroid disease in women, with prevalence rates 
ranging from 4 to 21%, whereas the rate in men ranges from 2.8 to 16% 
(Carnaris et al., 2000). 
          Thyroid disease increases with age. In the Colorado study, the 18-
year-olds had a prevalence rate of 3.5% compared with a rate of 18.5% for 
those ≥ 65 years of age. The prevalence of thyroid disease in diabetes has 
been estimated at 10.8%, with the majority of cases occurring as 
hypothyroidism (~30%) and subclinical hypothyroidism (~50%). 
Hyperthyroidism accounts for 12%, and postpartum thyroiditis accounts for 
11% (Wu,  2000). 
        There is a well known geographical dependency in thyroid diseases 
because of the different amounts of alimentary iodine intake that occur in 
different geographic locations (Lamfon, 2008). 
2.13. Diabetes mellitus and thyroid diseases: 
      Diabetes mellitus and thyroid diseases are the two common 
endocrinopathies seen in the adult population. With insulin and thyroid 
hormones being intimately involved in cellular metabolism and thus excess 
or deficit of either of these hormones could result in the functional 
derangement of the other (Sathish and Mohan, 2003). 
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2.14. Effect of Diabetes on Thyroid Function: 
          In euthyroid individuals with diabetes mellitus, the serum T3 levels, 
basal TSH levels and TSH response to thyrotropin releasing hormone (TRH) 
may all be strongly influenced by the glycemic status. Poorly controlled 
diabetes, both Type 1 and Type II, may induce a “Low T3 state” 
characterized by low serum total and free T3 levels, increase in reverse T3 
(rT3) but near normal serum T4 and TSH concentrations. Low serum T3 is 
due to reduced peripheral conversion of thyroxine (T4) to tri-iodothyronine 
(T3) via 5’ monodeiodination reaction. Studies indicate that it may be the 
long term diabetic control that determines the plasma T3 levels. Poorly 
controlled diabetes may also result in impaired TSH response to TRH or loss 
of normal nocturnal TSH peak. TSH responses and “low T3 state” may 
normalize with improvement in glycemic status but even with good diabetes 
control, the normal nocturnal TSH peak may not be restored in C-peptide 
negative patients i.e. those with totally absent pancreatic beta cell function 
(Sathish and Mohan, 2003). 
           Typically, blood glucose levels are unaffected by hypothyroidism 
because insulin sensitivity is not altered. In fact, in patients utilizing 
exogenous insulin, there may be a decrease in insulin requirements from 
reduced insulin degradation. Therefore, typically, glucose remains stable or 
improves while a person is hypothyroid. Once thyroid treatment is initiated, 
patient education and close observation is vital because normalization of the 
thyroid may potentially lead to higher blood glucose levels and loss of 
diabetes control. In contrast, hyperthyroidism causes insulin resistance and 
may unmask impaired glucose tolerance and diabetes in previously 
undiagnosed patients. Typically, blood glucose levels are abnormal and 
trend towards hyperglycemia until treatment is initiated. After the thyroid 
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function stabilizes, the glucose levels usually improve (Johnson and Duick, 
2002). 
2.15. Effects of Thyroid Hormone on Diabetes: 
         The effect on carbohydrate metabolism can potentially lead to 
disruptions in diabetes control. Although the glucose level does not always 
change, there can be an abnormal response to glucose tolerance testing in 
hyperthyroidism because glucose rises faster than normal. Additionally, 
excessive thyroid hormones increase the rate of digestive tract absorption 
and thyroid hormone levels and therefore increase insulin resistance and 
insulin degradation. In hyperthyroidism, glycogen synthesis and degradation 
increase, leading to decreased glycogen levels (Ober, 2000). 
          Glucose absorption is increased, as well as utilization and production. 
Peripheral tissues have increased rates of glucose uptake that can lead to the 
aforementioned exaggerated glucose peak during a timed glucose test. 
Insulin requirements are increased, and, if not addressed adequately, control 
can decompensate, leading to diabetic ketoacidosis. Additionally, in patients 
with undetected diabetes, hyperthyroidism can unmask diabetes because 
glucose levels can be abnormally elevated because of increased insulin 
resistance. Increased dosages of diabetes medications may be necessary in 
those already treated, until thyroid function is stabilized and resultant 
glucose stabilization occurs. In hypothyroidism, liver secretion of glycogen 
decreases, but so does degradation, leading to increased levels of glycogen. 
Absorption of glucose from the gastrointestinal tract is slowed, and glucose 
utilization is slowed in the peripheral tissues. The availability of 
gluconeogenic substrate is decreased. Additionally, the insulin half-life is 
prolonged, insulin levels are lower, and insulin secretion is reduced, which 
may lead to reduced insulin requirements. If exogenous insulin is not 
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decreased, hypoglycemia may occur. It is likely that glucose levels will 
stabilize during hypothyroidism treatment. But when thyroid function is 
normalized, this may lead to higher blood glucose levels and adverse effects 
on glycemic control (Johnson, 2006). 
       The prevalence of thyroid disease in type 2 diabetes is higher than in the 
general population (Ober, 2000). Whereas the Fremantle Diabetes Study 
found a 8.6% prevalence of subclinical hypothyroidism in women with type 
2 diabetes in Australia (Chubb et al., 2005). 
        A study of the prevalence of autoimmune thyroid disease in type 2 
diabetes in Jordan reported an overall prevalence rate of 12.5%, with 
subclinical hypothyroidism at 5% ( Radaideh et al., 2004). 
         In study in Nigeria, thyroid hormone levels were significantly lower in 
IDDM patients than in the control population and the NIDDM population. 
Subclinical hypothyroidism was present in 21% of the 28 IDDM patients. 
One patient was hypothyroid and another hyperthyroid. Of the 60 NIDDM 
patients, 5 (8.3%) had subclinical hypothyroidism (Cardoso et al., 1995). 
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CHAPTER THREE 
MATERIALS AND METHODS 
 
3.1. Subjects studied: 
      Eighty eight Sudanese type 2 diabetic patients(88) were randomly 
selected from Ribat University Hospital, Emtyaz Medical center and Bahri 
Diabetic Center. 
     Full information was taken from each subject about type, treatment, 
history of diabetes, family history about diabetes and other diseases and 
complications as shown in the instructed questionnaire ( appendix I). All 
subjects were under treatment or diet control. 
     Fourty (40) apparently healthy non- diabetic individuals were chosen as 
controls. All of the subjects(128) were not suffering from any endocrine 
disease and those with evidence of abnormality were excluded before 
sample collection. 
3.2. Collection of blood samples: 
Blood samples from patients and controls were taken under 
supervision of consultant physician and endocrinologist using adjustable 
repeating syringe (Eppendorf, Itamurge 65, Fed. Rep. Germany). Serum was 
separated in polystyrene assay (Eppendorf  polystyrene assay tubes code No 
5001 round bottomed tubes with a capacity of 5 ml).  
After obtaining informed consent from each subject, four ml of 
venous blood in dry syringe were collected after 12 hours overnight fasting 
period. The blood was divided into two tubes. 1 ml was collected in floride 
oxalate for glucose measurement and 3 ml were allowed to clot and 
immediately centrifuged at 2000 r.p.m. for 10 minutes. All serum samples 
were stored in refrigerator, tightly closed, at Sudan Atomic Energy 
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commission, radioisotopes laboratory until analyzed. Glucose and 
hemoglobin were measured immediately. 
3.3. Determination of fasting blood glucose:  
The glucose is oxidized to D — gluconate by the glucose oxidase 
(GOD) with the formation of hydrogen peroxide. In the presence of 
peroxidase (POD), a mixture of phenol and aminoantipyrine (4-AA) is 
oxidized by hydrogen peroxide, to form a red quinoneimine dye proportional 
to the concentration of glucose in the sample. 
B-D — glucose + H20 + 02 GOD D — Gluconate + H2O2 
4- AA + phenol H20,          Quinoneimine + H20 
                        POD 
Glucose was determined using the following Assay Protocol: 
• All reagent and samples was brought to room temperature. 
• In to labeled test tubes the following were pipetted. 
Tubes  Blank  Sample  Standard  
Mono reagent  1.0 ml  1.0 ml  1.0 ml 
Sample  - 10 µL  - 
Stand  - - 10µL 
 
• The tubes were mixed and incubated for 10 mm at room temperature. 
• The absorbance (A) of the samples and the standard were measured at 500 
mm against the blank. 
Glucose mg/dl = A sample! A standard X concentration of standard (l00 
mg/dL) 
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3.4. Measurement of pancreatic autoantibodies(Anti – GAD/IA2 pool 
ELISA Test): 
3.4.1. Materials: 
1. Microplate wells: Coated with antigens: 12 microplate strips each 
containing 8 individual breaks – off wells in a frame, ready for use 
2. Calibrator 1 – 6: 450/145/70/20/10/4 IU/ml (IgG, human), ready for use. 
3. Negative control: 0 IU/ml (IgG, human), ready for use. 
4. Positive control: (IgG, human, ready for use). 
5. Sample buffer: ready for use. 
6. GAD/IA2: biotin – labeled GAD and IA2.  
7. GAD/IA2 buffer: ready for use. 
8. Enzyme conjugate: peroxidase – labeled avidin, 20x concentrated. 
9. Conjugate buffer: ready for use. 
10. Wash buffer: 10 x concentrate. 
11. Chromogen/ substrate solution: TMB/ H2O2, ready for use. 
12. Stop solution: 0.25 M sulphuric acid, ready for use. 
3.4.2. Steps: 
1. 50 µl of the calibrators, negative and positive controls or patient samples 
were transferred into the individual microplate wells according to the 
pipetting protocol. 
2. 25 µl of sample buffer was added into each of the microplate wells used. 
The frame was covered and shaked for 5 seconds at 500 rpm, then incubated 
for 16 – 20 hours at 4°C - 8°C. 
3. Reagent wells were washed 3 times with 450 µl working strength wash 
buffer. 
4. The wash buffer in each well was left for 30 to 60 seconds per washing 
cycle and then the liquid in the wells were disposed by tapping it on 
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absorbent paper with the openings facing downwards to remove all residual 
wash buffer. 
5. 100 µl of GAD (biotin–labeled GAD) was pipetted into each of 
microplate wells. The frame was covered and incubated for 1 hour at room 
temperature on a microplate shaker set at 500 rpm. 
6. The wells were emptied. 
7. 100 µl of enzyme conjugate (peroxidase – labeled avidin) was pipetted 
into each of the microplate wells. 
8. The frame was covered and incubated for 20 minutes at room temperature 
on microplate shaker set at 500 rpm. 
9. The wells were emptied. 
10. 100 µl of chromogen/ substrate solution was pipetted into each of the 
microplate wells and then incubated for 20 minutes room temperature. 
11. 100 µl of stop solution was pipetted  into each of the microplate wells in 
the same order and at the same speed as the chromogen/ substrate solution 
was introduced. 
12. Photometeric measurement of the colour intensity was made at a 
wavelength of 450 nm and then 405 nm using a microplate reader within 5 
minutes of adding the stop solution. 
3.5. Measurement of thyroid hormones and thyroid related hormones: 
      All radioimmunoassay specific reagents for the measurement of thyroid 
and thyroid related hormones were supplied by the Department of Isotopes 
from China Institute for Atomic Energy (CIAE). 
      Serum T4 and T3 were measured by RIA kits, the components for each 
kit are as follow: radio labeled antigen (Tracer) I125-T4 or I125-T3, solutions, 
55 ml, red solution in baritone buffer with bovine serum albumin and ANS 
(8—anillino -1- naphthalene sulfonic acid) T4 or T3 - antibody suspension 
26 
 
with antimicrobial agent (Sodium azide). 6 vials T4 standard human serum 
with concentration (0.0— 20— 40— 80— 160_240 — nmol/L ) or 6 vial T3 
— standard human serum with antimicrobial agent with concentration (0.0, 
0.5, 1.6, 2.0, 4.0, 8.0 nmol I L) and magnatizable separating. 
IRMA is a radiolabeled antibody immunoradiometric assay, is best 
example of excess reagent method. It uses antibodies at an excess 
concentration in which a solid phase (Ab) was allowed to react with antigen 
(Ag) and then the complex formed was washed using buffer. Labeled 
antibody was then added to the medium to form a sandwich complex Ab-
Ag-Ab*. After attaining equilibrium, the complex was washed twice to 
remove excess labeled antibody and read in gamma counter for 60 seconds. 
The concentration of Ag reacted with the antibodies are determined using 
standard of Ag. 
3.5.1. Method for determination of total serum thyroxin (T4): 
The T4 and T3 radioimmunoassay method depends on the competition 
between I125 labeled T4 or T3 and T4 or T3 contained in standard or specimens 
to be assayed for affixed and limited number of T4 or T3 antibody binding 
sites. After the incubation, the amount of I125 labeled T4 or T3 bound to the 
antibody is inversely related to the amount of T4 or T3 present in the sample. 
By measuring the proportion of I 125 labeled T4 or T3 bound in the presence 
of reference standards containing various known amount of T4 or T3 the 
concentration of T4 or T3 present in unknown sample can be interpolated. 
The steps of the procedure can be summarized as follows. Sufficient test 
tubes used in assay were labeled in duplicates and arranged in assay rack, 
using the following protocol: 
• 50 µL sample or standard were pipetted into labeled tubes. 
• 500 µL I125-T4) solutions were added into each tubes. 
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• 500 µL antibody suspensions were dispensed into labeled tubes. 
All tubes were vortexed and mixed thoroughly using multi-tube 
vortexer SMIR (ALPHA laboratories, Serial No. 093647 Cat. No 2601) and 
incubated at 37 °C for 45 minutes. Then the test tubes rack was placed on 
magnetic separator and Multimix Major, (Luckam, Serial No. 424, Model 
No MF) for 10 minutes. The supernatant was decanted, tubes placed on pad 
of absorbent paper to drain for 5 min. Finally all tubes were counted with 
gamma counter for 60 seconds using Multi detector gamma counter. (PG-
RIA.MAS, Stratec Biochemical System AG, SN 2486000052). 
3.5.2. Method for determination of total serum triiodothyronine (T3): 
      Serum T3 was determined using the following Assay Protocol: 
Tubes used in assay were labeled in duplicate and arranged in assay rack, 
using the following protocol: 
• 50 µL were pipetted into the labeled tubes (standards, samples and Qcs) 
• 500µL (I125- T3) solution (red) were added into all tubes. 
• 500 µL T3 antibody suspension was added to all tubes. 
All tubes were vortexed and mixed thoroughly (using Multi-tube vortexer 
SMIR, ALPHA laboratories, Serial No. 093647 Cat.No 2601) and incubated 
at 37 °C for 60 minutes then the test tubes rack was placed on magnetic 
separator and Multimix Major (Luckam, Serial No. 424, Model No MF) for 
10 minutes. The supernatant was decanted and tubes placed on pad of 
absorbent paper to drain for 5 min. Finally all tubes were counted with 
gamma counter for 60 seconds using Multi detector gamma counter (PG-
RIA.MAS, Stratec Biochemical System AG, SN 2486000052). 
3.5.3. Measurement of thyroid stimulating hormone (TSH): 
Human TSH in serum was determined quantitatively by using 
magnetic separation reagents include I125 — anti — TSH (monoclonal ) 
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solution (red), magnetic TSH antibody (Polyclonal) suspension, TSH set of 
standards (A,B,C,D,E,F,G) with the following concentrations, (0.0, 0.28, 
1.1, 2.9, 10, 20, 90) mlU/L in lyophilized form. These standards were 
calibrated according to the international reference preparation of TSH (code 
MRRC 80, 1558). The kit also contains concentrated wash buffer (phosphate 
buffer) and locally prepared control samples. 
The following protocol was used to determine the concentration: 
.Tubes used in assay were labeled and arranged in assay rack. 
• 200µL of standards, controls, and unknown were pipetted in to the labeled 
tubes. 
• 50µL of (I125 anti —TSH) solution was added and then all tubes were 
vortexed thoroughly using Multi-tube vortex SMIR (ALPHA laboratories, 
Serial No. 093647 Cat. No 2601) and incubated 1 hour at 37 °C.  
• 500µL well mixed antibody suspension was added and mixed well, tubes 
were vortexed gently and incubated 1 hour at room temperature, the test 
tubes rack was placed on magnetic separator and Multimix Major (Luckam, 
Serial No. 424, Model No MF) for 10 minutes, then supernatant was 
decanted, the precipitant was washed using 1.0 ml wash buffer, the tubes 
were vortexed and replaced on magnetic separator allow to stand for 10 mm. 
Washing step was repeated, supernatant was decanted and drained 
thoroughly on absorbent paper and tubes were counted with gamma counter 
for 60 seconds using Multidetector gamma counter (PG-RIA.MAS, Stratec 
Biochemical System AG, SN 2486000052).  
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3.6. Method of Thyroid status classification: 
       Thyroid status are classified into five cateogories as shown in table 3.1. 
below:  
Table 3.1. Classification of thyroid function state: 
 
Thyroid status T3 nmol/L T4 nmol/L TSH mIU/L 
Normal Normal Normal Normal 
Hyperthyrodism > 150 >3.0 <0.4 
Subhyperthyroidism Normal Normal <0.4 
Hypothyrodism <50 <0.8 >4.0 
Subhypothyroidsm Normal Normal >4.0 
 
This method is adopted from Sudanese Atomic Energy Corporation, 
Khartoum, Sudan. 
2.7. Statistical Analysis: 
 Data was entered in and analyzed using statistical package of social 
sciences SPSS version 13.5. 
Numerical data was represented as means and standard deviation. The 
significance of the mean difference between two independent groups using 
student’s sample t test and one way ANOVA with p<0.05 considered 
significant. 
 Person correlation was performed to test linear relationship between 
numerical valuables. Proportional data was conducted using the chi-square 
test adjusted by pearson’s test.  
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CHAPTER FOUR 
RESULTS 
 
4.1. General findings:  
      This study was a descriptive longitudinal study.  The study groups were 
Insulin independent Diabetes mellitus,, who were compared with relative age 
healthy individual. 
      The study covered eighty eight Sudanese diabetic patients and fourty 
healthy controls in three centers. Ribat University Hospital (Khartoum), Bahri 
Diabetic Center (Khartoum North) and Imtyaz Diabetic Center (Omdurman). 
     While 57.2% of the patients were females, 41.8% were males. For control 
each sex was found to represent 50%.  69.3% of the patients have family 
history with disease duration ranged between 1-10 years. All of them received 
oral treatment (Insulin independence). 
      The mean age was 50.3 and 48.7 years for the patients and control groups 
respectively ranged between 40- 65 year.  
    Analysis was performed by determination of latent autoimmune disease 
(LADA) by measurement of Fasting Blood Glucose {FBG}, detection of 
autoantibody GAD 65/IA2 in type II diabetics and thyroid hormones {T3, T4 
and TSH} levels in the diabetic patients and the healthy individuals. 
4.2 Fasting Blood Glucose (FBG): 
Diabetics showed a higher FBG compared to healthy individuals with 
Mean values196.6± 59.4 and 83.9±83.9 mg/dl respectively. There was a 
significant difference between both values (0.00) as shown in table 4.1. Most 
data in Diabetics found between 100-300 mg/dl while most healthy data 
ranged between 80-120 mg/dl as shown in Figure 4.1. 
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4.3. Pancreatic autoantibodies (GAD 6/IA2): 
Nine patients showed GAD65/ IA2 autoantibodies (10.2%). The mean 
values of FBG were 153± 50 mg/dl and 199± 59mg/dl for positive and 
negative GAD65/IA2 respectively. No significant difference (P> 0.05) was 
observed  between GAD65/IA2 autoantibodies and FBG level in the blood  
as shown in table 4.2. 
The normal distribution of FBG ranged between 80-400 mg/dl for the 
negative GAD/IA2 diabetic patients and 80-220 mg/dl for the positive 
GAD/IA2 diabetic patients as shown in figure 4.2.  
4.4. Thyroid hormones levels: 
All control individuals did not show any clinical or subclinical 
disurbances in their thyroid functions. However, 64 of diabetic patients 
(72.2%) exhibited normal thyroid status, while 24 pateints (27.3%) had 
abnormal functions(Table4.1). They were 16 females and 8 males. 
Among the 24 subjects of thyroid disorders, the most common status 
was Subhyperthyroidism (normal T3 & T4 and low TSH levels) 14 cases 
(15.9%) followed by Hypothyroidism (low T3 & T4 levels) 5 cases (5.7%), 
Hyperthyrodism (high T3 & T4 levels) 4 cases (4.9% ) and finally 
Subhypothyroidism (normal T3 & T4 and high TSH levels)  1 case (1.1%) 
as shown in table 4.3 & figure 4.3.  
Thyroid hormones individually  showed different abnormalities. For 
T3, all healthy individuals and 75 diabetic patients (85.2%) showed normal 
thyroid functions, while 13 diabetic patients (14.7%) had abnormal T3 levels 
(4.5% were low &10.2 were high) (table 4.4). The mean values of T3 among 
healthy and diabetic groups were 2.3± 0.52 and 2.1±0.93 nmol/L 
respectively ( table 4.5). Normal distribution for T3 values ranged between 
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1-3.3 nmol/L and 1.7-3.0nmol/L for healthy individuals and diabetics 
respectively (figure 4.4). 
All T4 healthy individuals except one (1.1%) and 75 of diabetic 
patients (85.2%) showed normal thyroid functions, while 13 diabetic patients 
(14.7%) had abnormal T4 levels (5.7% were low & 9.1 were high) as shown 
in table 4.6. The mean values of T4 among healthy and diabetic groups were 
99.7± 20.5 and 103.4± 33.7 nmol/L respectively as shown in Table 4.7. 
Normal distribution for T4 values ranged between 75-125 nmol/L and 60- 
150 nmol/L for healthy individuals and diabetics respectively as shown in 
(figure 4.5). 
All TSH healthy individuals and 63 of diabetic patients (71.6%) 
showed normal thyroid functions while 25 diabetic patients (28.4%) had 
abnormal TSH levels (19.3% were low & 9.1% were high) as shown in 
figure 4.8. The mean values of TSH among healthy and diabetic groups were 
1.8± 0.5 and 1.4± 1.67 nmol/L, respectively and there was a significant 
difference between the two groups (table 4.9). Normal distribution for TSH 
values ranged between 1-1.25 mIU/L for healthy individuals while for 
diabetics most values  of patients found below 2mIU/L as shown in Figure 
4.6. 
There was a strong significant negative correlation between FBG level 
and TSH hormone (0.038), while there were no correlation observed 
between FBG level and thyroid hormones (T3 & T4) as shown in table 4.10. 
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Table 4.1. Mean values of FBG among diabetic and healthy 
groups.  
 
 
status N Mean
Std. 
Deviation
*P-value 
FBG 
mg/dl 
diabetic 
patients 88 196.6 59.4
0.000 
healthy 
individuals 40 83.9 14.6
*P value is significant < 0.05. 
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Fig 4.1. Normal distribution of FBG in healthy and diabetic groups. 
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Table 4.2. Mean values of FBG level among positive and negative 
GAD/IA2 autoantibodies in diabetic patients. 
  
 GAD65/IA2 N Mean 
Std. 
Deviation *P-value 
FBG 
mg/dl 
Positive 9 153.0 50.1 0.062 
Negative 79 199.8 59.1  
*P value is significant < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
Negative
Psitive
GAD65
400300200100
FBG mg/dl
20
15
10
5
0
Fr
eq
ue
nc
y
20
15
10
5
0
Fr
eq
ue
nc
y
Figure 4.2. Normal distribution of FBG among positive and negative 
GAD65/IA2 diabetics 
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Table 4.3. Thyroid function status among diabetic and healthy 
individuals: 
 
Status  *Groups Frequency Percent 
diabetic patients Normal 64 72.7 
  Subhypothyroidism 1 1.1 
  Hypothyroidism 5 5.7 
  Subhyperthyroidism 14 15.9 
  Hyperthyroidism 4 4.5 
  Total 88 100 
healthy individuals Normal 40 100 
* According to the method adopted from Sudanese Atomic Energy 
Corporation. 
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Fig 4.3. Thyroid status among diabetic patients. 
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Table 4.4. Mean values of T3 among diabetic and healthy groups.  
 
 
status N Mean
Std. 
Deviation
*P-value 
T3 
nmol/L 
diabetic 
patients 88 2.1 0.93
0.241 
healthy 
individuals 40 2.3 0.52
*P value is significant < 0.05. 
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Table 4.5. Mean values of T3 among diabetic and healthy groups.  
 
 
status N Mean
Std. 
Deviation
*P-value 
T3 
nmol/L 
diabetic 
patients 88 2.1 0.93
0.241 
healthy 
individuals 40 2.3 0.52
*P value is significant < 0.05. 
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Figure 4.4. Normal distribution of T3 among healthy and diabetic 
groups. 
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Table 4.6. Level of T4 among healthy and diabetic groups: 
T4.nmol/L       
Status     Frequency  Percent 
diabetic patients  Normal  75 85.2 
   Low  5 5.7 
   High  8 9.1 
   Total  88 100 
healthy individuals  Normal  39 97.5 
   Low  1 2.5 
   Total  40 100 
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Table 4.7. Mean values of T4 among diabetic and healthy groups.  
 
 
status N Mean
Std. 
Deviation
*P-value 
T4 
nmol/L 
diabetic 
patients 88 103.4 33.74
0.449 
healthy 
individuals 40 99.7 20.52
*P value is significant < 0. 
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Figure 4.5. Normal distribution of T4 among healthy and diabetic 
groups. 
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Table 4.8. Mean values of TSH among diabetic and healthy groups.  
 
 
status N Mean
Std. 
Deviation
*P-value 
TSH 
mIU/L 
diabetic 
patients 88 1.4 167
0.044 
healthy 
individuals 40 1.8 0.5
*P value is significant < 0. 
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Table 4.9. Mean values of TSH among diabetic and healthy groups.  
 
 
status N Mean
Std. 
Deviation
*P-value 
TSH 
mIU/L 
diabetic 
patients 88 1.4 167
0.044 
healthy 
individuals 40 1.8 0.5
*P value is significant < 0. 
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Figure 4.6. Normal distribution of TSH among healthy and diabetic 
groups 
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Table 4.10. Correlation of FBG with Thyroid hormones: 
(p < 0.05) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hormone Correlation  with FBG P-value 
T3 nmol/L -0.013 0.884 
T4 nmol/L 0.042 0.636 
TSH mIU/L -0.0184 *0.038 
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Chapter Five 
Discussion 
Diabetes mellitus is a major public health problem. There are two 
major types of DM: type 1 and type 2. The two forms have different genetic 
background, demographic and biochemical characteristics, pathogenic 
mechanisms and type of treatment. It is well known that the majority of 
those with type 1 DM have autoimmune bases for the pathogenesis of their 
DM, which is supported by the frequent presence of IA2 and GAD 
antibodies. Several studies have shown the increasing prevalence of Latent 
autoimmune disease of adults (LADA) which is one of the phenotypic 
expressions of the complex autoimmune polyendocrine syndrome (Akbar et 
al., 2006).  
Lack of insulin or insulin resistance prevents the efficient uptake and 
utilization of glucose by most cells of the body, except those of the brain. As 
a result, blood glucose concentration increases, cell utilization of glucose 
decreases and utilization of fats and proteins increases (Briscoe and Davis, 
2006; Guyton and Hall, 2006). 
 Diabetic patients showed a higher FBG level compared to healthy 
individuals with mean values 196.6± 59.4 and 83.9±83.9 mg/dl respectively 
with a significant difference (p=0.00). Furthermore, and the values in 
Diabetic patients had a wider range between 100- 300 mg/dl than most 
healthy values which found between 80-120 mg/dl. 
  This variation was possible due to absence or resistance to insulin. our 
results were similar to these obtained  by Yasmin et al., (2006) and  
Abdelgadir., (2006) who observed that the rest of diabetic population and the 
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FBG level were also elevated as an  indication for poor diabetic control 
status. 
 Diabetes mellitus is increasingly diagnosed among young adults 
worldwide. The etiological and phenotypic heterogeneity of diabetes in this 
age group poses diagnostic and therapeutic challenges to clinicians. The 
clinical spectrum of diabetes has not been adequately characterized among 
young adult Sudanese, amongst whom diabetes has emerged as an important 
public health problem. 
 Screening of patients over the age of 40 years, classified as having 
type 2 diabetes, has shown that about 10% were positive for at least one 
autoantibody specificity. The most prevalent autoantibodies were directed 
against GAD65 (GADA), which were found in 4% - 10% of the patients 
(Seissler, 2008). 
Many studies have shown that patients positive for GADA and/or ICA  
have a more rapid decline in C-peptide, fail oral agents, and require insulin 
treatment earlier. 
This study suggested that increased age, overweight and physical 
inactivity were strong risk factors for LADA as for type II diabetes. These 
findings suggested a role for insulin resistance in the pathogenesis of LADA. 
The study found that 10.2% of diabetic patients were positive to GAD65 
autoantibodies. This was similar to the finding reported by Fourlanous et al, 
(2005). However, other studies (Sanjeevi et al, 2003) showed higher 
prevalence (30%) and this could be related to difference in the 
histocompatibility (HLA) antigen, environmental factors or dietary habits. 
Further studies with HLA antigen typing in Sudanese type 2 diabetics are 
needed to study this interesting observation. 
51 
 
This study showed that LADA diabetics were 5 females and 4 males. 
It has been observed that LADA is significantly associated with younger age 
(that those patients ranged between 40-51 years) and shorter duration of 
diabetes (ranged between 1-5 years) and this was similar to (Akbar et al, 
2006). Thyroid disorders were detected in 3 GADA/IA2 patients while 6 had 
normal thyroid functions. 
It was clear that they had uncontrolled glucose levels despite of 
continuous oral treatment and changing of those drugs type and doses many 
times and this is attributed to the need of insulin injections treatment.  
 There was no relationship between GAD65 presence and FBG levels 
(p = 0.062). 
Diabetes patients have a higher prevalence of thyroid disorders than 
the normal population (Wu, 2000). Since thyroid hormones regulate 
metabolism and diabetes can alter metabolism of foodstuff, the metabolism 
of the organism may be further affected by the combination of thyroid 
disease and diabetes (Bernal and Refeloff, 1977; Notarbartolo et al, 1983; 
Wu, 2000).   
            The prevalence of thyroid (clinical or subclinical hypothyroidism or 
hyperthyroidism) was found to be 27.3% (24 patients). Our findings were 
significantly higher than those reported by previous studies (5-6% of 
hypothyroidism or hyperthyroidism) (Gray et al., 1979). However, the 
results were similar to wickman survey who found prevalence of 6.6% of 
thyroid dysfunction in diabetic community (Tunbridge et al., 1997). 
Cardoso et al (1995), found that 21% of diabetic type 2 patients have 
thyroid disturbances (Cardoso et al., 1995). In addition, Perros et al (1995), 
found in their survey 31.4% of thyroid dysfunction with no previously 
diagnosed thyroid pathology. 
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The control group showed no clincal or subclinical thyroid disorders. 
They were 16 females and 8 males.  
Thyroid hormones individually  showed different abnormalities. For 
T3, all healthy individuals and 75 of diabetic patients (85.2%) showed 
normal thyroid functions while 13 diabetic patients (14.7%) had abnormal T3 
levels and the mean values of T3 in diabetics (2.3± 0.52) nmol/L was lower 
than healthy group and (2.1±0.93) nmol/L without significant difference. 
This variation was du to poorly controlled diabetes which resulted in a low 
T3 (Sathish and Mhan, 2003). This was possible due to influence of diabetes 
at the conversion of thyroxin (T4) to triiodothyronine (T3) in the peripheral 
tissues. 
 T4 healthy individuals, except one (1.1%), and 75 of diabetic patients 
(85.2%) showed normal thyroid functions while 13 diabetic patients (14.7%) 
had abnormal T4 levels(5.7% were low & 9.1 were high) and the mean 
values of T4 among healthy and diabetic groups were (99.7± 20.5) and 
(103.4± 33.7) nmol/L respectively. No significant variation was observed in 
T4 level, which were similar to the  finding observed by Hamid et al., (1998) 
and Giampietro et al., (1985). 
Alteration in thyroid hormones indicates the charachteristic of low T3 
syndrome when is due to marked hyperglycaemia that decreased the activity 
and concentration of hepatic T4-5 which a characteristic of  finding of low T3 
syndrome (Gilani et al.,1984). 
Altered thyroid hormone levels have been previously reported in 
insulin-requiring diabetic patients before and after treatment (Saunders et al, 
1978) where mean plasma T4 and T3 levels were significantly different 
between untreated diabetics and normal control subjects. Following insulin 
treatment, T3 and T4 levels rose in these patients. 
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All TSH healthy individuals and 63 of diabetic patients (71.6%) 
showed normal thyroid functions while 25 diabetic patients (28.4%) had 
abnormal TSH levels (19.3% were low & 9.1 were high). Other reports 
investigated the prevalence of abnormal TSH concentration in type 2 DM 
and it was found in 31% (Celani et al., 1994) and this difference may be 
attributed to large sample size. A study in Sudan reported that thyroid 
disorders comprised 13% in both types of diabetes (Agarib, 2008).  
 The mean values of TSH among healthy and diabetic groups were 
(1.8± 0.5) and (1.4± 1.67) nmol/L respectively and there was a significant 
difference between the two groups (p=0.044) and most diabetic values 
distribution found below 2mIU/L. this was due to poor glycemic control and 
agreed with other studies(Tunbridge et al., 1997; Smithson,1998).  
There was a strong significant negative correlation between FBG level 
and TSH hormone (0.038), which was similar to the findings obtained by 
Cardoso et al. (1995).On the other hand, no correlation was observed 
between FBG level and thyroid hormones (T3 & T4). 
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Conclusion 
             
        The study concluded that the investigation of thyroid hormones will be 
very useful in those patients with type 2 Dm. MoreoverGAD65 should 
 be performed in every patient with adult onset DM to identify subjects with 
LADA. Additionally, Insulin treatment should be implemented in LADA 
patients. 
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Recommendations 
 
• GAD65 were significantly increased in classified T2DM patients so it 
must be tested as routine investigation to avoid misclassification and 
determine the proper treatment decision. 
• There is little information of diabetes and thyroid dysfunction in 
Sudan and hence there is a need for more scientific studies. 
• Use of large sample size and time period for the next studies to get 
more confirmed results 
• Investigate other Beta cell autoantibodies and thyroid autoantibodies 
to detect autoimmune polyendocrine syndromes. 
• Periodic screening for T2DM patients for general endocrine functions 
and autoimmune status. 
• Serum TSH is the best screening test for thyroid functions in type 2 
diabetes patients. 
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Appendix 1: 
 
Questionnaire 
 
Name………………………………….Hospital…………….ID…………….. 
 
Age…………………………………….Sex………...………………………. 
 
Tribe…………………………………..Tel…..……....................................... 
 
Residence………………………………work……………………………….. 
 
Disease history……………………………………………………………….. 
 
Family history………………………………………………………………... 
 
Treatment……………………………………………………………………. 
 
Other diseases……………………………………………………………….. 
 
Diabetic control……………………………………………………………… 
 
Clinical investigation…………………………………………………………. 
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Appendix 2: Thyroid hormones (T3. T4. TSH) and GAD 65/IA2 in 
diabetic patients:  
 
NO T3 nmol/L T4 nmol/L TSH mIU/L GAD65/IA2 FBG mg/dl 
1 1.5 90 0.5  300 
2 1.9 1.9 1.4  224 
3 2.6 90 1.1  179 
4 1.9 99 1.3  300 
5 2.6 124 0.9  260 
6 1.8 80 1.0  180 
7 1.1 93 0.2 Positive 134 
8 1.7 114 1.5  210 
9 1.9 86 1.1  200 
10 0.1 33 6.6  178 
11 1.3 85 1.6  200 
12 2.1 100 1.6  110 
13 0.5 33 5.2  205 
14 4.5 173 0.1 positive 147 
15 1.2 90 1.2  163 
16 2.2 96 1.8  192 
17 2.6 110 1.1  224 
18 2.4 120 1.6  215 
19 1.9 82 1.4  236 
20 2.6 70 1.8  271 
21 1.5 99 0.6  220 
22 4.4 180 0.2 Positive 256 
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23 1.9 111 0.8  192 
24 2.6 80 0.5  204 
25 1.6 72 0.4  300 
26 1.3 99 1.2  228 
27 1.7 121 1.3  105 
28 0.1 25 6.1 positive 160 
29 1.5 80 0.5  250 
30 2.5 82 1.3  103 
31 2.9 96 1.6  184 
32 3.9 170 0.3  300 
33 1.6 114 0.8  125 
34 1.2 147 0.6  256 
35 3.7 80 1.6  175 
36 2.1 142 1.4  244 
37 2.6 132 0.3  236 
38 2.0 108 0.1  138 
39 1.9 135 1.1 positive 116 
40 1.9 85 0.6  164 
41 2.9 94 1.2  130 
42 2.7 112 0.6  233 
43 2.5 151 0.7  251 
44 2.6 90 1.6  181 
45 1.8 113 0.4  302 
46 1.4 106 1.1  185 
47 2.6 90 0.5  206 
48 4.5 180 0.3  115 
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49 2.6 146 0.6  220 
50 1.3 86 1.8  200 
51 2.9 104 1.6  140 
52 2.7 117 2.2  220 
53 3.0 100 1.3  160 
54 2.5 140 0.5  215 
55 2.9 108 0.6  201 
56 2.3 85 0.1 positive 129 
57 4.3 175 0.2  260 
58 1.8 86 0.3  249 
59 4.6 194 0.9  244 
60 1.4 89 1.6  190 
61 2.6 85 0.3  170 
62 3.8 120 1.1  230 
63 2.1 81 1.5  230 
64 1.5 95 1.6  88 
65 2.6 89 1.2  260 
66 2.5 112 0.6  270 
67 1.6 100 1.8  129 
68 1.7 96 4.8  143 
69 2.8 130 0.3  230 
70 1.6 96 0.2  239 
71 2.8 136 0.6  300 
72 2.0 118 0.8  241 
73 1.5 76 0.2 Positive 100 
74 1.4 86 0.9  96 
67 
 
75 1.5 110 0.2 positive 130 
76 2.9 131 7.6  156 
77 1.4 85 0.5  200 
78 1.0 113 1.6  125 
79 3.2 160 0.4  110 
80 1.7 117 6.1  370 
81 1.5 90 1.2  169 
82 1.6 86 1.4  204 
83 1.1 71 1.3  196 
84 1.8 132 0.2  113 
85 1.9 80 0.1 positive 109 
86 1.5 70 5.0  236 
87 0.2 40 8.6  220 
88 1.4 96 1.2  123 
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Appendix 3: Thyroid hormones (T3. T4. TSH) & Fasting Blood Glucose 
(FBG) in healthy individuals  
 
NO T3 nmol/L T4 nmol/L TSH mIU/L FBG mg/dl 
1 1.7 97 1.1 100 
2 1.9 105 1.6 69 
3 2.4 11 1.9 88 
4 1.8 88 1.8 70 
5 2.8 106 2.3 83 
6 2.5 120 1.0 91 
7 3.0 99 2.1 102 
8 2.6 117 1.9 114 
9 2.9 102 2.2 65 
10 2.8 96 0.9 77 
11 1.5 82 1.6 69 
12 2.6 126 2.1 84 
13 2.4 105 2.2 90 
14 2.1 120 1.3 102 
15 2.9 94 1.8 105 
16 3.0 78 1.3 79 
17 2.9 89 1.1 81 
18 1.3 96 2.1 71 
19 1.9 109 2.4 88 
20 2.5 86 1.6 96 
21 2.6 115 1.9 109 
22 1.9 98 2.7 68 
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23 1.4 109 2.1 78 
24 2.0 123 1.2 92 
25 2.1 81 1.9 99 
26 2.6 96 1.4 100 
27 2.8 130 1.1 82 
28 2.0 106 2.1 75 
29 2.9 89 2.5 82 
30 1.6 73 1.3 70 
31 2.9 108 1.8 79 
32 2.9 132 1.9 85 
33 1.6 118 1.5 40 
34 1.9 91 2.1 80 
35 2.6 85 1.3 76 
36 1.6 100 2.6 69 
37 2.0 109 1.8 78 
38 2.8 116 2.7 85 
39 1.9 89 2.6 79 
40 2.6 93 1.3 106 
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Appendix 4: Normal range of the measured parameters: 
 
Parameter Normal range 
 
T3 0.8 -3.0 nmol/L 
 
T4 60-160 nmol/L 
 
GAD 65 
 
Negative:  <4 IU/ml 
Positive:   >4 IU/ml 
TSH 0.4 – 4.0 mIU/L 
 
Fasting blood glucose 70 – 120 mg/dl 
 
 
 
 
